The latest failure, in colorectal cancer, follows a recent disappointment in second-line liver.

Tempest Therapeutics confirms an earlier success with its lead project, and this time investors respond.

After generating unexpectedly positive TIGIT data Roche moves to launch a phase 3 trial.